The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Optimal treatment regimens for multiple myeloma
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, shares his insights into determining the optimal treatment regimen in third-line myeloma. Dr Kaufman describes the two most common treatment regimens being currently used: a pomalidomide or carfilzomib base, plus an anti-CD38 monoclonal antibody and dexamethasone. Following this, Dr Kaufman focuses on newly emerging data regarding the addition of selinexor, and the importance of choosing the best dosing schedule for each treatment combination to obtain the optimal response in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
